Why all the fuss about canagliflozin?

Australian researchers have discovered that a relatively new drug used to lower blood glucose in type 2 diabetes patients also significantly reduces their risk of cardiovascular and kidney disease.

Their study of more than 10,000 patients in 30 countries has found that canagliflozin, a SGLT2 inhibitor, reduces the overall risk of cardiovascular disease by 14% and heart failure hospitalisation by 33%, compared with the placebo.

It also has a significant impact on the progression of renal